Two Florida entities will jointly develop a potential diagnostic breakthrough tool as the Florida Institute for the Commercialization of Public Research announced today that it has finalized a funding agreement with Orlando-based Aviana Molecular Technologies.
The agreement allows Aviana, a development-stage company working on user-friendly technology to develop a first-level point of care diagnostic for infections, to continue developing its unique smartphone-enabled platform. Aviana’s technology, which is universally compatible with existing smartphones and other computing platforms, leads to an end system using a disposable biosensor cartridge. Combined with a reusable portable detection reader, the system may be used in any health care setting by a non-lab trained technician.
"Aviana believes that its technology can provide affordable diagnostics in a connected world with rapid detection of specific infections within 15 to 20 minutes," Aviana President and CEO Vanaja Ragavan said. "Such rapid and efficient diagnosis of infections can help in treatment and spread of diseases."
Florida Institute for the Commercialization of Public Research, with offices in Boca Raton and Gainesville, is a nonprofit collaborating with technology licensing and commercialization offices in Florida's universities and private research institutions. It aims to leverage a $2 billion-plus research base and form companies suitable for investment, creating clean jobs in new industries that drive the global economy.
"Aviana's technology is simple, adaptable and can be useful in reducing the spread of infections," Institute CEO Jamie Grooms said. "Conceptually, it can be developed to be used in both highly sophisticated health systems but also in resource-limited environments, and the Institute is delighted to support the Aviana team as it advances the commercialization of this promising new technology."
Aviana Molecular Technologies is headquartered in Orlando’s Central Florida Research Park.
3651 FAU Boulevard
Boca Raton, FL 33431